HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal Gastric Cancer Cases

被引：10
作者：
Liu, Xiaoyan [1 ]
Wang, Xiaoling [1 ]
Wang, Bo [1 ]
Ren, Guoping [1 ]
Ding, Wei [1 ]
机构：
[1] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Pathol, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China
来源：
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY | 2016年 / 24卷 / 07期
关键词：
gastric cancer; fluorescence in situ hybridization; HER2/neu; PROTEIN EXPRESSION; BREAST-CANCER; NEU ONCOGENE; RECEPTOR; ADENOCARCINOMA; VALIDATION; PROGNOSIS; CARCINOMA; PATTERNS;
D O I：
10.1097/PAI.0000000000000219
中图分类号：
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号：
100101 ;
摘要：
Objective: To determine the frequency of HER2/neu amplification and the relationship between HER2/neu expression and clinicopathologic features in gastric cancers scored immunohistochemistry (IHC) 2+. Methods: A total of 122 gastric cancer cases scored IHC 2+ were retrospectively analyzed for HER2 amplification by fluorescence in situ hybridization (FISH). The correlation between HER2/neu expression and clinicopathologic features was analyzed. Results: HER2/neu gene was amplified in 17 out of the 122 gastric cancer samples. The concordance rate between IHC and FISH was 13.9%. HER2/neu status was correlated with the age of patients (P<0.05). Polysomy of CEP17 was demonstrated in 46 cases, 11 of which (23.91%) were amplified for HER2/neu. Within the subgroups, a correlation between CEP17 polysomy and the depth of invasion was observed (P<0.05). Conclusions: The results highlight the necessity of FISH test for further categorization when gastric cancer cases are scored 2+ by IHC. The value of HER2/neu for a potential role as a negative prognostic factor in the equivocal gastric cancer cases is limited.
引用
收藏
页码：459 / 464
页数：6
相关论文
共 25 条
  • [1] Bang YJ, 2010, LANCET, V376, P1302
  • [2] TYROSINE KINASE RECEPTOR WITH EXTENSIVE HOMOLOGY TO EGF RECEPTOR SHARES CHROMOSOMAL LOCATION WITH NEU ONCOGENE
    COUSSENS, L
    YANGFENG, TL
    LIAO, YC
    CHEN, E
    GRAY, A
    MCGRATH, J
    SEEBURG, PH
    LIBERMANN, TA
    SCHLESSINGER, J
    FRANCKE, U
    LEVINSON, A
    ULLRICH, A
    [J]. SCIENCE, 1985, 230 (4730) : 1132 - 1139
  • [3] The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast - A fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study
    Downs-Kelly, E
    Yoder, BJ
    Stoler, M
    Tubbs, RR
    Skacel, M
    Grogan, T
    Roche, P
    Hicks, DG
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (09) : 1221 - 1227
  • [4] HER2 in Resected Gastric Cancer: Is there Prognostic Value?
    Fisher, Sarah B.
    Fisher, Kevin E.
    Squires, Malcolm H., III
    Patel, Sameer H.
    Kooby, David A.
    El-Rayes, Bassel F.
    Cardona, Kenneth
    Russell, Maria C.
    Staley, Charles A., III
    Farris, Alton B., III
    Maithel, Shishir K.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2014, 109 (02) : 61 - 66
  • [5] Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer
    He, Chao
    Bian, Xue-Yi
    Ni, Xing-Zhi
    Shen, Dan-Ping
    Shen, Yan-Ying
    Liu, Hua
    Shen, Zhi-Yong
    Liu, Qiang
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (14) : 2171 - 2178
  • [6] Assessment of a HER2 scoring system for gastric cancer:: results from a validation study
    Hofmann, M.
    Stoss, O.
    Shi, D.
    Buettner, R.
    van de Vijver, M.
    Kim, W.
    Ochiai, A.
    Rueschoff, J.
    Henkel, T.
    [J]. HISTOPATHOLOGY, 2008, 52 (07) : 797 - 805
  • [7] HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature
    Jorgensen, Jan Trost
    Hersom, Maria
    [J]. JOURNAL OF CANCER, 2012, 3 : 137 - 144
  • [8] Targeted HER2 Treatment in Advanced Gastric Cancer
    Jorgensen, Jan Trost
    [J]. ONCOLOGY, 2010, 78 (01) : 26 - 33
  • [9] Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world
    Kamangar, Farin
    Dores, Graca M.
    Anderson, William F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (14) : 2137 - 2150
  • [10] An overview of HER2
    Lohrisch, C
    Piccart, M
    [J]. SEMINARS IN ONCOLOGY, 2001, 28 (06) : 3 - 11
123